Laurent Fischer - Dec 8, 2021 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
CEO, President and Director, Director
Signature
Laurent D. Fischer, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
ADVM
Transactions as of
Dec 8, 2021
Transactions value $
$45,609
Form type
4
Date filed
12/10/2021, 04:26 PM
Previous filing
Aug 10, 2021
Next filing
Mar 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADVM Common Stock Purchase $19.1K +10.7K +1.5% $1.79 723K Dec 8, 2021 Direct F1, F2
transaction ADVM Common Stock Purchase $26.5K +14.3K +1.98% $1.85 737K Dec 9, 2021 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.75 to $1.80. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
F2 Includes 3,000 shares purchased on May 20, 2021 inadvertently not reflected as held on the Reporting Person's prior Form 4 and 3,170 shares purchased on November 22, 2021, in each case pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated.
F3 Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.845 to $1.85. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.